R T Chung

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint HIV increases HCV replication in a TGF-beta1-dependent manner
    Wenyu Lin
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 134:803-11. 2008
  2. pmc Inhibition of HCV by the serpin antithrombin III
    Mohammed Asmal
    Division of Viral Pathogenesis, BIDMC, Boston, MA 02215, USA
    Virol J 9:226. 2012
  3. pmc Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients
    Raymond T Chung
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    HIV Clin Trials 13:70-82. 2012
  4. ncbi request reprint Assessment of efficacy of treatment in HCV: infection and disease
    Raymond T Chung
    GRJ 825, Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Hepatol 44:S56-9. 2006
  5. ncbi request reprint Acute hepatitis C virus infection
    Raymond T Chung
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    Clin Infect Dis 41:S14-7. 2005
  6. pmc Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop
    Raymond T Chung
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Hepatology 47:306-20. 2008
  7. ncbi request reprint Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects
    Raymond T Chung
    Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    AIDS 16:1915-23. 2002
  8. pmc Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C
    Raymond T Chung
    Massachusetts General Hospital, GI Unit, Warren 1007, Boston, MA 02114, USA
    Hepatology 52:1906-14. 2010
  9. ncbi request reprint Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    Raymond T Chung
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 351:451-9. 2004
  10. pmc Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system
    R T Chung
    Gastrointestinal Unit, Cancer Center, and Hospital for Children, Massachusetts General Hospital, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 98:9847-52. 2001

Detail Information

Publications94

  1. doi request reprint HIV increases HCV replication in a TGF-beta1-dependent manner
    Wenyu Lin
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Gastroenterology 134:803-11. 2008
    ..It has remained unclear how HIV, a nonhepatotropic virus, accelerates the progression of liver disease by HCV...
  2. pmc Inhibition of HCV by the serpin antithrombin III
    Mohammed Asmal
    Division of Viral Pathogenesis, BIDMC, Boston, MA 02215, USA
    Virol J 9:226. 2012
    ..We have recently shown that ATIII, a serine protease inhibitor (serpin), has broad antiviral properties...
  3. pmc Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients
    Raymond T Chung
    Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    HIV Clin Trials 13:70-82. 2012
    ....
  4. ncbi request reprint Assessment of efficacy of treatment in HCV: infection and disease
    Raymond T Chung
    GRJ 825, Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Hepatol 44:S56-9. 2006
    ..Eventually, it is anticipated that genotype-phenotype correlations will permit selection of optimized antiviral regimens once virus specific enzymatic inhibitors have been approved...
  5. ncbi request reprint Acute hepatitis C virus infection
    Raymond T Chung
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114 2696, USA
    Clin Infect Dis 41:S14-7. 2005
    ..Further work is needed to develop more-accurate assays for acute HCV infection, to define host and viral factors that predict outcome and to define the optimal duration and regimen of therapy...
  6. pmc Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop
    Raymond T Chung
    Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Hepatology 47:306-20. 2008
  7. ncbi request reprint Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects
    Raymond T Chung
    Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
    AIDS 16:1915-23. 2002
    ..We analysed changes in HCV RNA and the frequency of hepatotoxicity in co-infected patient enrolling in AIDS Clinical Trials Group trials, and determined whether HCV impairs successful immune reconstitution in these populations...
  8. pmc Association of host pharmacodynamic effects with virologic response to pegylated interferon alfa-2a/ribavirin in chronic hepatitis C
    Raymond T Chung
    Massachusetts General Hospital, GI Unit, Warren 1007, Boston, MA 02114, USA
    Hepatology 52:1906-14. 2010
    ..However, after adjusting for drug exposure and accounting for duration of therapy, only neutropenia was independently associated with virologic response...
  9. ncbi request reprint Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
    Raymond T Chung
    Massachusetts General Hospital, Boston, MA 02114, USA
    N Engl J Med 351:451-9. 2004
    ..We conducted a multicenter, randomized trial comparing peginterferon plus ribavirin with interferon plus ribavirin for the treatment of chronic hepatitis C in persons coinfected with HIV...
  10. pmc Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system
    R T Chung
    Gastrointestinal Unit, Cancer Center, and Hospital for Children, Massachusetts General Hospital, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 98:9847-52. 2001
    ..The availability of a cell-based test for viral replication will facilitate screening of inhibitory compounds, analysis of IFN-resistance mechanisms, and analysis of virus-host cell interactions...
  11. ncbi request reprint Approach to the management of allograft recipients following the detection of hepatitis B virus in the prospective organ donor
    R T Chung
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Am J Transplant 1:185-91. 2001
    ....
  12. ncbi request reprint Pegylated interferon alpha-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C
    Andrew S Ross
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Clin Transplant 18:166-73. 2004
    ..Hematologic toxicity and dose modifications were frequent. Our experience with antiviral therapy for HCV post-OLT remains disappointing but PEG-IFN + RBV appears to produce VR in a sizable portion of IFN + RBV non-responders...
  13. doi request reprint Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up
    Kathleen E Corey
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Hepatology 50:1030-7. 2009
    ..A significant portion of successfully treated patients experience LDL and cholesterol rebound to levels associated with increased coronary disease risk. Lipids should be carefully monitored in persons receiving antiviral therapy...
  14. pmc Acute hepatitis C infection lowers serum lipid levels
    K E Corey
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Viral Hepat 18:e366-71. 2011
    ..Levels may increase above pre-infection baseline lipid levels and should be monitored...
  15. ncbi request reprint Mutations in the NS5A region do not predict interferon-responsiveness in american patients infected with genotype 1b hepatitis C virus
    R T Chung
    Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston 02114 2696, USA
    J Med Virol 58:353-8. 1999
    ..Overall, NS5a is not as integral a determinant of interferon responsiveness as previously suggested...
  16. ncbi request reprint Detection of hepatitis C virus (HCV) in serum and peripheral-blood mononuclear cells from HCV-monoinfected and HIV/HCV-coinfected persons
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 192:258-65. 2005
    ..These data suggest differential regulation of HCV RNA in the serum and PBMC compartments and may partially explain the limited HCV antiviral response rates observed in coinfected persons...
  17. ncbi request reprint Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection
    Camilla S Graham
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    AIDS 19:767-73. 2005
    ..To test the hypothesis that antigen-specific interferon (IFN)gamma responses are correlated with milder liver disease in subjects coinfected with HIV-1 and hepatitis C virus (HCV)...
  18. pmc Full-breadth analysis of CD8+ T-cell responses in acute hepatitis C virus infection and early therapy
    Georg M Lauer
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Charlestown, 02129, USA
    J Virol 79:12979-88. 2005
    ..These data suggest that broad CD8(+) T-cell responses alone may be insufficient to contain HCV replication, and also that early therapy is effective independent of such responses...
  19. ncbi request reprint Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients
    Kenneth E Sherman
    Department of Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
    Gastroenterology 128:313-27. 2005
    ..HCV-monoinfected patients. Reasons for this remain unclear. This study evaluated kinetic parameters and treatment responses in co-infected vs monoinfected patients...
  20. ncbi request reprint HIV/Hepatitis B and C co-infection: pathogenic interactions, natural history and therapy
    R T Chung
    Gastrointestinal Unit, Massachussetts General Hospital, Boston, USA
    Antivir Chem Chemother 12:73-91. 2001
    ..Finally, we will discuss the rapidly evolving area of therapy, with particular attention to many of the newer agents now in clinical trials, as well as combinations of these agents...
  21. ncbi request reprint Hepatitis C virus (HCV) diversity in HIV-HCV-coinfected subjects initiating highly active antiretroviral therapy
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Infect Dis 189:1472-81. 2004
    ..These data suggest that there are several mechanisms by which suppression of HIV replication and a reconstituted immune system influence diversity of HCV in HIV-HCV-coinfected subjects...
  22. ncbi request reprint Management strategies using pharmacogenomics in patients with severe HCV-1b infection: a decision analysis
    Hisashi Moriguchi
    Division of Advanced Medical Technology and Intellectual Property Policy, Research Center for Advanced Science and Technology, University of Tokyo, 4 6 1 Komaba Meguro ku, Tokyo, Japan 153 8904
    Hepatology 36:177-85. 2002
    ..0 mEq/mL. In conclusion, use of decision analysis models can help in therapeutic decisions for patients with HCV-1b...
  23. ncbi request reprint GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype
    Carolynne Schwarze-Zander
    Department of Internal Medicine I, University of Bonn, Bonn, Germany
    J Infect Dis 194:410-9. 2006
    ..We therefore investigated (1) the prevalence and genotype of GBV-C in hepatitis C virus (HCV)/HIV-coinfected patients and (2) the impact of HCV treatment on GBV-C RNA clearance...
  24. pmc The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin
    A A Butt
    Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA
    Aliment Pharmacol Ther 33:1234-44. 2011
    ..The association of anaemia with outcomes in the HCV/HIV coinfected persons undergoing HCV treatment remains unclear...
  25. ncbi request reprint A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication
    Sun Suk Kim
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Gastroenterology 132:311-20. 2007
    ..Thus, the identification of more effective and better tolerated agents is a high priority. We applied chemical biology to screen small molecules that regulate HCV...
  26. ncbi request reprint Recurrent allograft HCV presenting as acute cellular rejection: successful management with interferon and ribavirin alone
    Jessica Y Leung
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Clin Transplant 17:275-83. 2003
    ..We conclude that in cases suggestive of ACR, careful consideration should be given to treatment for recurrent HCV in lieu of or in concert with intensive immunosuppression...
  27. ncbi request reprint Management of hepatitis C virus coinfection in HIV-infected persons
    Jacqueline G O'Leary
    Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
    AIDS Read 16:313-6, 318-20. 2006
    ..The risk of interactions between drugs used to treat hepatitis C and those for HIV, such as between ribavirin and didanosine, needs to be considered before initiating treatment in HIV-HCV-coinfected patients...
  28. pmc Cell-based models of sustained, interferon-sensitive hepatitis C virus genotype 1 replication
    Yoichi Hiasa
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, GRJ 816, 55 Fruit Street, Boston, MA 02114, USA
    J Virol Methods 132:195-203. 2006
    ....
  29. ncbi request reprint Intrahepatic cytokine expression is downregulated during HCV/HIV co-infection
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    J Med Virol 78:202-7. 2006
    ..These data suggest that a defect in cytokine activation may occur in HCV/HIV co-infected persons that limits efficient clearance of HCV from the liver...
  30. pmc Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection
    Jason T Blackard
    Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH 45267, and Gastrointestinal Unit, Massachusetts General Hospital, Boston, USA
    J Infect Dis 195:1765-73. 2007
    ..It is provocative to speculate that extrahepatic HCV diversity may be an important determinant of treatment response and thus warrants additional study, particularly during HCV/HIV coinfection...
  31. ncbi request reprint The magnitude and breadth of hepatitis C virus-specific CD8+ T cells depend on absolute CD4+ T-cell count in individuals coinfected with HIV-1
    Arthur Y Kim
    Partners AIDS Research Center and Infectious Disease Unit, Massachusetts General Hospital, Harvard Medical School, 149 13th St 5th Fl, Boston, MA 02129, USA
    Blood 105:1170-8. 2005
    ....
  32. pmc Hepatic SOCS3 expression is strongly associated with non-response to therapy and race in HCV and HCV/HIV infection
    Kyung Ah Kim
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    J Hepatol 50:705-11. 2009
    ..The response rates of HCV infection to interferon therapy vary depending on viral and host factors. We hypothesized that key regulators of the IFN signaling pathway are predictive of treatment outcome...
  33. ncbi request reprint Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects
    Caroline M Behler
    Department of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143 1270, USA
    Clin Infect Dis 44:1375-83. 2007
    ....
  34. ncbi request reprint Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors
    Thomas D Schiano
    The Recanati Miller Transplantation Institute, The Mount Sinai Hospital, New York, NY, USA
    Hepatology 42:1420-8. 2005
    ..The trend toward a greater initial viral load decrease in patients with LD grafts and the significantly sharper increase suggest that the liver plays a predominant role in both HCV clearance and replication...
  35. pmc Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV
    D K Wong
    Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Virol 75:1229-35. 2001
    ..The high degree of concordance of HCV epitopes identified from liver and PBMC suggests that this strategy is a reasonable alternative to liver biopsy for characterizing the CTL response to HCV in chronically infected persons...
  36. doi request reprint Pilot study of postexposure prophylaxis for hepatitis C virus in healthcare workers
    Kathleen E Corey
    Harvard Medical School, Boston, MA, USA
    Infect Control Hosp Epidemiol 30:1000-5. 2009
    ..We sought to determine the safety, tolerability, and acceptance of postexposure prophylaxis with peginterferon alfa-2b in healthcare workers (HCWs) exposed to blood from HCV-infected patients...
  37. ncbi request reprint Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection
    Camilla S Graham
    Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115, USA
    AIDS 20:345-51. 2006
    ..To test the hypothesis that hepatitis C virus (HCV)-specific interferon (IFN)gamma immune responses are correlated with HCV virological response following treatment in subjects with HIV-1 and HCV co-infection...
  38. doi request reprint Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop
    Alexander Monto
    Department of Medicine, San Francisco Veterans Affairs Medical Center, San Francisco, California 94121, USA
    Am J Gastroenterol 105:989-1004; quiz 988, 1005. 2010
    ..This article summarizes that conference...
  39. doi request reprint Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance
    Aymin Delgado-Borrego
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Liver Transpl 14:193-201. 2008
    ..Higher HCV RNA levels were associated with earlier elevations in HOMA-IR. Collectively, these results provide strong evidence that HCV induces the development of IR...
  40. pmc Human immunodeficiency virus type 1-hepatitis C virus coinfection: intraindividual comparison of cellular immune responses against two persistent viruses
    Georg M Lauer
    Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    J Virol 76:2817-26. 2002
    ..In addition, they show a consistent and profound impairment in cellular immune responses to HCV compared to HIV-1 in HIV-1-HCV-coinfected persons...
  41. pmc High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome
    Victoria Kasprowicz
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA
    J Virol 82:3154-60. 2008
    ..Our results suggest that an analysis of PD-1 expression alone is not sufficient to predict infection outcome or to determine T-cell functionality in HCV infection...
  42. ncbi request reprint Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis
    Joel R Pekow
    Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Cancer 109:2490-6. 2007
    ..The authors sought to determine whether hepatic steatosis is associated with hepatocellular carcinoma (HCC) in a cohort of patients with hepatitis C-related cirrhosis...
  43. ncbi request reprint Remission of hepatitis C virus-associated cryoglobulinemic glomerulonephritis with interferon alfa-2b and ribavirin combination therapy after liver transplantation
    Tabo Sikaneta
    Renal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Transplantation 74:1767-8. 2002
  44. ncbi request reprint Protein kinase R is increased and is functional in hepatitis C virus-related hepatocellular carcinoma
    Yoichi Hiasa
    Gastrointestinal Unit, Cancer Center and Hospital for Children, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Am J Gastroenterol 98:2528-34. 2003
    ..To evaluate the role of PKR in HCV-related hepatocellular carcinoma (HCC), we compared PKR and related protein expression in paired tumor (T) and surrounding nontumor (NT) tissue...
  45. ncbi request reprint Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial
    Anna S F Lok
    Division of Gastroenterology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 0362, USA
    Clin Gastroenterol Hepatol 5:245-54. 2007
    ....
  46. ncbi request reprint Peginterferon alpha-2a improved the hepatitis C virologic response in concurrent HIV and chronic hepatitis C virus infections
    Francesca J Torriani
    ACP J Club 142:A12; author reply A13. 2005
  47. ncbi request reprint Rethinking hepatitis C viral kinetics: Insights into host-virus interactions in 'difficult-to-treat' groups and implications for novel treatment approaches
    Elaine Yeung
    J Hepatol 43:748-50. 2005
  48. pmc Viral hepatocarcinogenesis
    W L Tsai
    Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Oncogene 29:2309-24. 2010
    ..Most HCC develops in the cirrhotic liver, but the linkage between cirrhosis and HCC is likely multifactorial. In this review, we summarize current knowledge regarding the pathogenetic mechanisms of viral HCC...
  49. ncbi request reprint Characterization of full-length hepatitis C virus genotype 4 sequences
    J Timm
    Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital, Boston, MA, USA
    J Viral Hepat 14:330-7. 2007
    ..Here we describe seven unique HCV genotype 4a full genomes, in addition to a single genotype 4d genome, and characterize their sequence diversity in relation to other more closely characterized HCV genotypes...
  50. doi request reprint Acute liver failure: mechanisms of hepatocyte injury and regeneration
    Anna Rutherford
    Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women s Hospital, Boston, MA 02115, USA
    Semin Liver Dis 28:167-74. 2008
    ....
  51. ncbi request reprint New antiviral therapies for hepatitis C
    Jacqueline O'Leary
    GI Unit, Massachusetts General Hospital, Boston 02114, USA
    Expert Rev Anti Infect Ther 2:235-43. 2004
    ..This article reviews modifications of current therapies, outlines the viral life cycle and focuses on novel therapeutic agents currently being studied...
  52. doi request reprint Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis
    Kenneth K Tanabe
    Division of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114 2696, USA
    JAMA 299:53-60. 2008
    ..Overexpression of epidermal growth factor (EGF) in the liver induces transformation to hepatocellular carcinoma in animal models. Polymorphisms in the EGF gene modulate EGF levels...
  53. ncbi request reprint Hepatic schistosomiasis
    Karin L Andersson
    Karin L Andersson, MD, MPH Gastrointestinal Unit, Massachusetts General Hospital, GRJ7, 55 Fruit Street, Boston, MA 02114, USA
    Curr Treat Options Gastroenterol 10:504-12. 2007
    ..For these reasons, nonselective shunt surgery such as the proximal splenorenal or the transjugular intrahepatic portosystemic shunt should not be performed in patients with advanced hepatic schistosomiasis...
  54. doi request reprint Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection
    Barbara H McGovern
    Division of Infectious Diseases, Lemuel Shattuck Hospital, Jamaica Plain, MA, USA
    Hepatology 48:1700-12. 2008
    ..Applying concepts learned in HIV therapeutics will hopefully lead to a prudent and cautious path in HCV treatment paradigms, particularly with respect to drug resistance...
  55. ncbi request reprint Interferon-alpha therapy in liver transplant recipients: lack of association with increased production of anti-HLA antibodies
    Francesca Cardarelli
    Renal and Transplantation Units, Departments of Medicine and Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Am J Transplant 4:1352-6. 2004
    ..In this study, LTRs receiving IFN did not have an increased frequency of anti-HLA antibodies. This may partially explain the safety of IFN previously reported in LTRs requiring antiviral therapy...
  56. doi request reprint Apolipoprotein B-dependent hepatitis C virus secretion is inhibited by the grapefruit flavonoid naringenin
    Yaakov Nahmias
    Center for Engineering in Medicine, Shriners Burns Hospital, Boston, MA, USA
    Hepatology 47:1437-45. 2008
    ..CONCLUSION: These results suggest a novel therapeutic approach for the treatment of HCV infection...
  57. pmc Coinfection with HIV-1 and HCV--a one-two punch
    Arthur Y Kim
    Division of Infectious Diseases and the Ragon Institute of MGH, MIT, and Harvard, Boston, Massachusetts, USA
    Gastroenterology 137:795-814. 2009
    ..Gaining insight into the mechanisms that underlie the immunopathogenesis of these persistent viral infections could lead to new therapeutic strategies for patients with HCV/HIV-1 coinfection...
  58. doi request reprint IgG4-associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material
    Vikram Deshpande
    The James Homer Wright Pathology Laboratories, Massachusetts General Hospital, Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA
    Mod Pathol 22:1287-95. 2009
    ..On a liver biopsy, the histological features of IgG4-associated cholangitis may be distinctive, and in conjunction with IgG4 immunohistochemical stain, may help distinguish this disease from primary sclerosing cholangitis...
  59. pmc The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort
    Barham K Abu Dayyeh
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Dig Dis Sci 56:564-8. 2011
    ..Both animal and limited human studies have shown that RAS inhibition with angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor-1 [AT-1] blockers (ARBs) has antifibrogenic properties...
  60. pmc Outcomes and treatment of acute hepatitis C virus infection in a United States population
    Kathleen E Corey
    Medical Services, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Gastroenterol Hepatol 4:1278-82. 2006
    ..However, the outcome of acute hepatitis C infection in United States cohorts is not well-characterized...
  61. doi request reprint Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis
    Karin L Andersson
    Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02114, USA
    Clin Gastroenterol Hepatol 6:1418-24. 2008
    ..We assessed the costs, clinical benefits, and cost effectiveness of US surveillance and alternative strategies for HCC in cirrhosis using a computer-based state transition model with parameters derived from available literature...
  62. ncbi request reprint Serum apoptosis markers in acute liver failure: a pilot study
    Anna E Rutherford
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
    Clin Gastroenterol Hepatol 5:1477-83. 2007
    ..We sought to determine whether circulating apoptotic markers are altered in acute liver failure (ALF), differ with etiology, or predict clinical outcome in this condition...
  63. pmc Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system
    Ana Maria Contreras
    Gastrointestinal Unit, Massachusetts General Hospital and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02114, USA
    J Virol 76:8505-17. 2002
    ..Finally, the latter result suggests that our replication model may be useful for identifying agents capable of driving replicating virus into error catastrophe...
  64. ncbi request reprint Hepatitis C Virus in the HIV-infected patient
    Karin Andersson
    Department of Gastroenterology, Blake 4, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
    Clin Liver Dis 10:303-20, viii. 2006
    ....
  65. ncbi request reprint Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999)
    Julie C Servoss
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, 02114, USA
    J Acquir Immune Defic Syndr 43:320-3. 2006
    ..7; P < 0.003). In conclusion, this study identified known and previously unreported risk factors for severe hepatotoxicity that should be considered before the initiation of ART...
  66. pmc Spontaneous control of HCV is associated with expression of HLA-B 57 and preservation of targeted epitopes
    Arthur Y Kim
    Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, GRB 504, Boston, Massachusetts 02114, USA
    Gastroenterology 140:686-696.e1. 2011
    ..We aimed to determine the correlations between these alleles and natural outcomes of HCV and determine associated key T-cell responses...
  67. ncbi request reprint Rapidly progressive fibrosing cholestatic hepatitis--hepatitis C virus in HIV coinfection
    Peter M Rosenberg
    Department of Pathology, Massachusetts General Hospital, Boston 02114, USA
    Am J Gastroenterol 97:478-83. 2002
    ..FCH may in part explain the accelerated development of cirrhosis previously observed among coinfected patients. Clinicians should remain vigilant for FCH in the HIV/HCV population and consider antiviral treatment in this setting...
  68. ncbi request reprint Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver
    Kenneth K Tanabe
    Department of Surgical Oncology, Massachusetts General Hospital, USA
    N Engl J Med 353:401-10. 2005
  69. pmc Impaired hepatitis C virus-specific T cell responses and recurrent hepatitis C virus in HIV coinfection
    Arthur Y Kim
    Partners AIDS Research Center and Infectious Disease Division, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Med 3:e492. 2006
    ..Here we examined the effect of a lymphotropic virus, HIV-1, on the ability of coinfected patients to maintain spontaneous control of HCV infection...
  70. ncbi request reprint Hepatitis C and B viruses: the new opportunists in HIV infection
    Raymond T Chung
    Harvard Medical School and Massachusetts General Hospital, Boston, MA, USA
    Top HIV Med 14:78-83. 2006
    ..Results of HCV and HBV treatment trials in HIV-coinfected patients and strategies for patient management are discussed herein...
  71. ncbi request reprint The role of early viral decline in the treatment of hepatitis C in HIV-1-coinfected persons
    Minhee Kang
    J Acquir Immune Defic Syndr 46:371-3. 2007
  72. ncbi request reprint Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain
    Patrick Yachimski
    AIDS Read 14:568-9. 2004
  73. ncbi request reprint The interferon sensitivity determining region in the era of combination therapies and the rational use of such therapies for patients with HCV genotype 1b infection
    Hisashi Moriguchi
    Gastroenterology 125:1284-6. 2003
  74. doi request reprint Hepatitis C virus replication is inhibited by 22beta-methoxyolean-12-ene-3beta, 24(4beta)-diol (ME3738) through enhancing interferon-beta
    Yoichi Hiasa
    Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan
    Hepatology 48:59-69. 2008
    ..Interferon-beta knockdown by small interfering RNA abrogated the anti-HCV effect of ME3738. Moreover, the anti-HCV effects were synergistic when ME3738 was combined with IFN-alpha...
  75. ncbi request reprint Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group
    Kenneth E Sherman
    Hepatology and Liver Transplant Medicine, Division of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, 45267, USA
    Clin Infect Dis 34:831-7. 2002
    ..5%. Genotype 1 was found in 83.3% of infected patients. Median HCV RNA level was 6.08x106 IU/mL. High virus loads and genotype 1 prevalence may be important to interferon-based antiviral response rates among coinfected patients...
  76. ncbi request reprint Posttransplant diabetes mellitus in liver transplant recipients: risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality
    S Baid
    Department of Medicine, Massachusetts General Hospital, Harvard Medical Schoool, Boston, MA 02114, USA
    Transplantation 72:1066-72. 2001
    ..In approximately half of the HCV (+) patients with PTDM, the onset of PTDM was related to the recurrence of allograft hepatitis. Improvement in glycemic control was achieved in the patients who responded to antiviral therapy...
  77. pmc Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain
    Wenyu Lin
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Virol 80:9226-35. 2006
    ....
  78. pmc Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers
    Cheryl L Day
    Howard Hughes Medical Institute, Partners AIDS Research Center, Boston, Massachusetts, USA
    J Clin Invest 112:831-42. 2003
    ..Moreover, they show that rare populations of memory CD4 T cells can be studied ex vivo in human diseases...
  79. ncbi request reprint Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C
    Herbert L Bonkovsky
    Department of Medicine, University of Connecticut Health Center, Farmington, Connecticut, USA
    Gastroenterology 131:1440-51. 2006
    ....
  80. pmc Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen
    Lee F Peng
    GI Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
    Antimicrob Agents Chemother 51:3756-9. 2007
    ..5 microM). We then synthesized an analog of these compounds with optimized activity...
  81. ncbi request reprint Viral factors associated with cytokine expression during HCV/HIV co-infection
    Jason T Blackard
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    J Interferon Cytokine Res 27:263-9. 2007
    ..Further studies are warranted to identify noninvasive markers of liver disease for the clinical management of HCV disease, particularly when liver biopsies have not been performed or are contraindicated...
  82. pmc Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients
    Thomas Kuntzen
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Hepatology 48:1769-78. 2008
    ....
  83. pmc Broad specificity of virus-specific CD4+ T-helper-cell responses in resolved hepatitis C virus infection
    Cheryl L Day
    Partners AIDS Research Center, Massachusetts General Hospital, 149 13th Street, Charlestown, MA 02129, USA
    J Virol 76:12584-95. 2002
    ..Moreover, these data provide important parameters for evaluation of candidate HCV vaccines, and provide rationale for immunotherapy in chronic HCV infection...
  84. ncbi request reprint Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation
    Aymin Delgado-Borrego
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
    Transplantation 77:703-10. 2004
    ..However, the pathogenetic basis for this association has not been established. We sought to evaluate the association between insulin resistance (IR), beta-cell dysfunction, and HCV among orthotopic liver transplant (OLT) recipients...
  85. ncbi request reprint Hepatitis C virus expression suppresses interferon signaling by degrading STAT1
    Wenyu Lin
    Gastrointestinal Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Gastroenterology 128:1034-41. 2005
    ..We used an HCV cell-based expression model to examine the interaction between HCV protein expression and host type I IFN signaling components in the Jak-STAT kinase pathway...
  86. pmc Immunologic evidence for lack of heterologous protection following resolution of HCV in patients with non-genotype 1 infection
    Julian Schulze zur Wiesch
    Partners AIDS Research Center, Infectious Disease Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA
    Blood 110:1559-69. 2007
    ....
  87. pmc CD8 epitope escape and reversion in acute HCV infection
    Joerg Timm
    Partners AIDS Research Center, Massachusetts General Hospital, Harvard Medical School, Bldg 149, 13th St, Rm 6618 B, Boston, MA 02114, USA
    J Exp Med 200:1593-604. 2004
    ..Together, these data indicate that viral escape from CD8+ T cell responses occurs during human HCV infection and that acute immune selection pressure is of sufficient magnitude to influence HCV evolution...
  88. ncbi request reprint Microarrays and prediction of interferon response in chronic hepatitis C: not yet ready for prime time
    Elaine Yeung
    Clin Gastroenterol Hepatol 3:1192-4. 2005
  89. pmc HCV synergizes with body weight in the promotion of insulin resistance
    A Delgado-Borrego
    Gastroenterology and Nutrition Unit, Department of Medicine, Children s Hospital Boston, Boston, MA, USA
    J Viral Hepat 18:135-41. 2011
    ..HCV therefore synergizes with weight in the promotion of IR. Steatosis was not a prerequisite for the development of IR, implying that HCV's effects on IR may be independent of steatosis...
  90. pmc Early treatment improves outcomes in acute hepatitis C virus infection: a meta-analysis
    K E Corey
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA, USA
    J Viral Hepat 17:201-7. 2010
    ..Based on these findings, we would advocate a 12 week period of observation for spontaneous clearance before treatment initiation. If no clearance has occurred by 12 weeks, treatment should be initiated...
  91. ncbi request reprint Liver transplantation outcomes for early-stage hepatocellular carcinoma: results of a multicenter study
    Jessica Y Leung
    Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA
    Liver Transpl 10:1343-54. 2004
    ..Regardless of which criteria are adopted to define eligibility, strict adherence to the criteria is important to achieve acceptable outcomes...
  92. pmc Treatment failure in hepatitis C: mechanisms of non-response
    Andrew W Tai
    Gastrointestinal Unit, Massachusetts General Hospital and Harvard Medical School, WRN 1007, 55 Fruit Street, Boston, MA 02114, USA
    J Hepatol 50:412-20. 2009
    ..Our progress in understanding the molecular underpinnings of interferon treatment failure in HCV infection has resulted in several promising and novel treatment strategies for HCV treatment non-responders...
  93. ncbi request reprint Spontaneous resolution of chronic hepatitis C virus disease after withdrawal of immunosuppression
    Ma Somsouk
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, 32 Fruit Street, Boston, MA 02114, USA
    Gastroenterology 124:1946-9. 2003
    ..This case underscores the importance of restoration of the immune system in the control of hepatitis C virus viremia and disease progression and the need to minimize or obviate immunosuppression in organ transplant recipients...
  94. pmc Suppressor of cytokine signaling 3 suppresses hepatitis C virus replication in an mTOR-dependent manner
    Run Xuan Shao
    Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Virol 84:6060-9. 2010
    ....

Research Grants14

  1. HIV-Hepatitis C Virus Interactions and Pathogenesis
    Raymond Chung; Fiscal Year: 2009
    ..These studies will shed considerable light on HIV-HCV pathogenic interactions and offer a means of productively disrupting these interactions. ..
  2. Patient-Oriented Research on Hepatitis in Special Populations
    Raymond Chung; Fiscal Year: 2007
    ..By developing investigators committed to patient-oriented research, Dr. Chung has strong confidence that they will follow suit in mentoring their own fellows and faculty, in so doing creating a highly desirable multiplier effect. ..
  3. HIV-Hepatitis C Virus Interactions and Pathogenesis
    Raymond Chung; Fiscal Year: 2007
    ..These studies will shed considerable light on HIV-HCV pathogenic interactions and offer a means of productively disrupting these interactions. ..
  4. Chemical Genetics:Cellular Regulators of HCV (RMI)
    Raymond Chung; Fiscal Year: 2004
    ..Second, discovery of hit compounds that positively or negatively regulate HCV replication will ultimately help lead to identification of novel cellular targets that can be exploited to further interrupt the viral lifecycle. ..
  5. NOVEL ANIMAL MODELS OF HCV-RELATED HEPATOCARCINOGENESIS
    Raymond Chung; Fiscal Year: 2003
    ..Together, these models will help provide insights into the factors responsible for this devastating complication of chronic HCV infection. ..
  6. HIV-Hepatitis C Virus Interactions and Pathogenesis
    Raymond T Chung; Fiscal Year: 2010
    ..These studies will shed considerable light on HIV-HCV pathogenic interactions and offer a means of productively disrupting these interactions. ..